Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives
United States. Government Accountability Office, issuing body. United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, issuing body.
Washington, D.C. : U.S. Government Accountability Office, October 3, 2017
Drug Approval -- statistics & numerical data
Drugs, Investigational -- therapeutic use
Health Services Accessibility
Investigational New Drug Application
United States. Food and Drug Administration.
The National Library of Medicine believes this item to be in the public domain.
1 online resource (1 PDF file (5 pages))
NLM Unique ID:
See catalog record
Metadata (Dublin Core)